LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2122 ◽

2021 ◽

Vol 32 ◽

pp. S1321

Author(s):

Y-L. Wu ◽

Q. Zhou ◽

M. Chen ◽

O. Jiang ◽

D. Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Unresectable Stage ◽

Phase Iii Study

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

C3-03: Randomized, phase III Study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small-cell lung cancer (NSCLC): WJTOG0105

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283204.17566.c5 ◽

2007 ◽

Vol 2 (8) ◽

pp. S365-S366 ◽

Cited By ~ 1

Author(s):

Kimihide Yoshida ◽

Hisao Uejima ◽

Miyako Satouchi ◽

Shinzoh Kudoh ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Stage Iii ◽

Thoracic Radiotherapy ◽

Small Cell Lung ◽

Unresectable Stage ◽

Phase Iii Study

Download Full-text

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1098 ◽

2019 ◽

Vol 25 (10) ◽

pp. 3193-3193

Author(s):

Nicholas Thatcher ◽

Jerome H. Goldschmidt ◽

Michael Thomas ◽

Michael Schenker ◽

Zhiying Pan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71346-0 ◽

2007 ◽

Vol 5 (4) ◽

pp. 362 ◽

Cited By ~ 3

Author(s):

W. Eberhardt ◽

M. Reck ◽

J. vonPawel ◽

P. Zatloukal ◽

R. Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Multicentre Phase ◽

Phase Iii Study

Download Full-text

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Lung Cancer ◽

10.1016/j.lungcan.2016.06.019 ◽

2016 ◽

Vol 99 ◽

pp. 94-101 ◽

Cited By ~ 7

Author(s):

Egbert F. Smit ◽

Yi-Long Wu ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial

Clinical Lung Cancer ◽

10.1016/j.cllc.2021.09.010 ◽

2021 ◽

Author(s):

John V. Heymach ◽

Tetsuya Mitsudomi ◽

David Harpole ◽

Mike Aperghis ◽

Stephanie Jones ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Controlled Study ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer

Oncotarget ◽

10.18632/oncotarget.6871 ◽

2016 ◽

Vol 7 (7) ◽

pp. 8422-8431 ◽

Cited By ~ 2

Author(s):

Qian Zhao ◽

Zhongtang Wang ◽

Wei Huang ◽

Qiang Wang ◽

Shuzeng Yu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Stage Iii ◽

Small Cell Lung ◽

Hyperfractionated Radiotherapy ◽

Unresectable Stage ◽

Phase Iii Study

Download Full-text

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

SpringerPlus ◽

10.1186/s40064-015-1067-7 ◽

2015 ◽

Vol 4 (1) ◽

Cited By ~ 8

Author(s):

Constantin Volovat ◽

Igor M Bondarenko ◽

Oleg A Gladkov ◽

Reiner Elsässer ◽

Anton Buchner ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Multicenter Study ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8056 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8056-8056 ◽

Cited By ~ 8

Author(s):

Lyudmila Bazhenova ◽

Giuseppe Giaccone ◽

John J. Nemunaitis ◽

Erzsébet Juhász ◽

Rodryg Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study ◽

International Multicenter

Download Full-text

Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8046 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8046-8046 ◽

Cited By ~ 1

Author(s):

Egbert F. Smit ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

Ji Feng Feng ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

C3-03: Randomized, phase III Study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small-cell lung cancer (NSCLC): WJTOG0105

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial

Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy.

Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).

Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial